Personal and societal health quality lost to tuberculosis

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Miller, Thaddeus L ^a,b   McNabb, Scott J N ^c   Hilsenrath, Peter ^a   Pasipanodya, Jotam ^a,b   Weis, Stephen E ^a,b,d  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c CDC   (United States)

^d Tarrant County Public Health Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; QUALITY ADJUSTED LIFE YEAR; TUBERCULOSIS CONTROL; COHORT ANALYSIS; HEALTH SURVEY; MIDDLE AGED; PATHOPHYSIOLOGY; TUBERCULOSIS;

ADULT; COHORT STUDIES; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; TUBERCULOSIS;

EID: 65249108154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005080     Document Type: Article

References (43)

1. Reichman LB (1991) The U-shaped curve of concern. Am Rev Respir Dis 144: 741-742.
2. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA (1995) Tuberculosis in New York City - turning the tide. N Engl J Med 333: 229-233.
3. Landesman SH (1993) Commentary: tuberculosis in New York City - the consequences and lessons of failure. Am J Public Health 83: 766-768.
4. Coker R (1998) Lessons from New York's tuberculosis epidemic. Tuberculosis is a political as much as a medical problem - and so are the solutions. BMJ 317: 616-620.
5. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC (1996) The role of cost-effectiveness analysis in health and medicine. JAMA 276: 1172-1177.
6. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, et al. (1995) Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 15: 369-390.
7. American Thoracic Society (1994) Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 149: 1359-1374.
8. Taylor Z (2000) The cost-effectiveness of screening for latent tuberculosis infection. Int J Tuberc Lung Dis 4(12): S127-S133.
9. Schwartzman K, Oxlade O, Barr RG, Grimard F, Acosta I, et al. (2005) Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 353: 1008-1020.
10. Pasipanodya JG, Miller TL, Vecino EM, Munguia G, Garmon R, et al. (2007) Pulmonary impairment after tuberculosis. Chest 131: 1817-1824.
11. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Bae S, et al. (2007) Using the St. George's Respiratory Questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis. Chest 132: 1591-1598.
12. Weis S, Miller T, Hilsenrath P, Moonan PK (2005) Comprehensive cost description of tuberculosis care. Int J Tuberc Lung Dis 9: 467-470.
13. Miller TL, Hilsenrath P, Lykens K, McNabb SJ, Moonan PK, et al. (2006) Using cost and health impacts to prioritize the targeted testing of tuberculosis in the United States. Ann Epidemiol 16: 305-312.
14. Miller TL, Reading JA, Hilsenrath P, Weis SE (2000) What are the costs of suspected but not reported tuberculosis? Ann Epidemiol 16: 777-781.
15. Mauchand R, Tousinart P, Chang H (1999) Cost-effectiveness of screening compared to case finding approaches in tuberculosis in long-term care facilities for the elderly. Int J Epidemiol 28: 563-570.
16. Hansel NN, Merriman B, Haponik EF, Diette GB (2004) Hospitalizations for tuberculosis in the United States in 2000: predictors of in-hospital mortality. Chest 126: 1079-1086.
17. World Health Organization. Health State Valuations for the Susceptible Population (by age, sex and WHO epidemiological sub-region). Available: http://www.who.int/choice/demography/health_valuations/en/index.html. Accessed 2006 Mar 12.
18. Centers for Disease Control and Prevention (2005) Reported tuberculosis in the United States, 2004. Atlanta, GA: U.S. Department of Health and Human Services, CDC.
19. Centers for Disease Control and Prevention. United States Life Tables 2002. Available: http://www.cdc.gov/nchs/data/dvs/life2002.pdf. Accessed 2006 Mar 15.
20. Cocchiarella L, Andersson GBJ (2000) Guides to the evaluation of permanent impairment. 5th ed. Chicago: American Medical Association. 613 p.
21. Miller WF, Scacci R (1981) Pulmonary function assessment for determination of pulmonary impairment and disability evaluation. Clin Chest Med 2(3): 327-341.
22. Crapo R, Morris AH, Gardner RM (1981) Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 123: 659-664.
23. McHugh LG, Milberg A, Whitcomb ME, Schoene RB, Maunder RJ (1994) Recovery of function in survivors of the acute respiratory distress syndrome. Am J Respir Crit Care Med 150: 90-94.
24. Niskanen M, Ruokonen E, Takala J, et al. (1999) Quality of life after prolonged intensive care. Crit Care Med 27: 1132-1139.
25. Vecino M, Pasipanodya JG, Bae S, Munguia G, Miller TL, Drewyer G, Weis SE, Weis SE. Stability of Pulmonary Impairment After Tuberculosis. Manuscript in review, Spring 2009.
26. Keeler EB, Cretin S (1983) Discounting of life-saving and other nonmonetary effects. Manage Sci 29: 300-306.
27. American Thoracic Society (2002) Understanding costs and cost-effectiveness in critical care. Am J Respir Crit Care Med 165: 540-550.
28. Graham JD (2003) Valuing Health: An OMB Perspective. Available: http:// www.whitehouse.gov/omb/inforeg/rff⊃eech_feb13.pdf. Accessed 2006 July 14.
29. van Praag BMS, Ferrer-i-Carbonell ADA (2008) Happiness quantified: a satisfaction calculus approach. Oxford University Press. 370 p.
30. Harvard Center for Risk Analysis Cost-utility analyses published from 1976 to 2001, with ratios converted to 2002 US dollars. The Cost-Effectiveness Analysis Registry [Internet]. (Boston), Harvard School of Public Health. Available: http://www.hsph.harvard.edu/ cearegistry. Accessed 2006 Jun 12.
31. CDC Division of Tuberculosis Elimination National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. QuantiFERON®-TB Gold Test. Available: http://www.cdc.gov/tb/pubs/tbfactsheets/QFT.htm. Accessed 2007 Sep 15.
32. World Health Organization. Global Tuberculosis Control - Surveillance, Planning, Financing. Aavilable: http://www.who.int/tb/publications/ global_report/2007/pdf/full.pdf. Accessed 2006 March 13.
33. Jamison DT, Breman JG, Measham AR, Alleyne G, Evans D (1993) Disease control priorities in developing countries. 2nd ed. New York: Oxford University Press. 278 p.
34. Sterling TR, Zhao Z, Khan A, Chaisson RE, Schluger N, et al. (2006) Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis 10: 542-549.
35. Garcia-Garcia Mde L, Ponce-De-Leon A, Garcia-Sancho MC, Ferreyra-Reyes L, Palacios-Martinez M, Fuentes J, et al. (2002) Tuberculosis-related deaths within a well-functioning DOTS control program. Emerg Infect Dis 8: 1327-1333.
36. Tocque K, Convrey RP, Bellis MA, Beeching NJ, Davies PD (2005) Elevated mortality following diagnosis with a treatable disease: tuberculosis. Int J Tuberc Lung Dis 9: 797-802.
37. Cooper AB, Ferguson ND, Hanly PJ, Meade MO, Kachura JR (1999) Longterm follow-up of survivors of acute lung injury: lack of effect of a ventilation strategy to prevent barotraumas. Crit Care Med 27: 2616-21.
38. Gross CR, Weinert CR (2001) Selecting measures for assessing quality of life after intensive care. In: Matalon S, Sznajder JI, eds. Etiology and treatment of acute lung injury: from bench to bedside. Amsterdam: IOS Press. pp 50.
39. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC (2003) Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow-up study. Thorax 58: 388-393.
40. Gross CR, Weinert CR (2001) Selecting measures for assessing quality of life after intensive care. In: Matalon S, Sznajder JI, eds. Etiology and treatment of acute lung injury: from bench to bedside. Amsterdam: IOS Press. pp 52-53.
41. Comstock GW (1999) How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 3: 847-850.
42. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America (2003) Treatment of tuberculosis. MMWR 52(RR-11): 1-77.
43. American Thoracic Society (1999) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161(1): 5221-5268.